William Blair analyst Matthew Phipps initiated coverage of shares of Pieris with an Outperform rating.
Pieris' Anticalin platform, for which several large pharma companies have contributed upfront capital and future milestone payments, continues to be undervalued by the Street, Phipps said in a Wednesday note.
Anticalins-branded proteins are artificial proteins derived from lipocalins found in blood plasma and other body fluids that naturally bind, store and transport a wide spectrum of molecules, according to Pieris. This provides specificity and affinity against a wide spectrum of targets.
Peris' lead bispecific program PRS-343 combines a CD137-specific Anticalin with a HER2-targeting antibody in a bid to transport an anti-CD137 therapeutic protein to the tumor microenvironment. William Blair expects proof-of-concept data in the second half of 2018.
"We also believe there is significant value in the company's collaboration with AstraZeneca plc (ADR) (NYSE: AZN) for PRS-060, an inhaled Anticalin targeting IL-4Rα for the treatment of severe asthma," the analyst said.
The valuation of Pieris shares does not reflect the potential of the company's lead assets, Phipps said.
"In particular, we believe PRS-343 and PRS-060, which both entered clinical studies in 2017, have significant potential, and initial proof-of-concept data will further validate Pieris's platform."
The Price Action
Over the past year, Pieris shares have soared about 284 percent.
At the time of writing the shares were up 6.79 percent at $7.39.
Attention Biotech Investors: Brace For These January PDUFA Events
Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades
Latest Ratings for PIRS
|Jan 2018||William Blair||Initiates Coverage On||Outperform|
|May 2017||Rodman & Renshaw||Initiates Coverage On||Buy|
|Aug 2016||Roth Capital||Assumes||Buy|
View More Analyst Ratings for PIRS
View the Latest Analyst Ratings
See more from Benzinga
- JPMorgan Turns Selective On Dry Bulk Carriers, Downgrades Diana Shipping And Navios Maritime Partners
- 5 Weed Stocks To Watch In 2018
- R.F. Lafferty: U.S. Silica Offers About 45% Upside Potential
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.